Current and emerging breast cancer biomarkers

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Breast cancer treatment has evolved with personalized therapies guided by predictive and prognostic biomarkers.
• Molecular biomarkers are crucial for tumor prediction and treatment strategies in breast carcinoma.
• Traditional prognostic factors are complemented by molecular insights for improved patient outcomes.

Purpose of the Study:

• To review the role of molecular biomarkers in advancing breast cancer treatment.
• To highlight frequent genetic alterations in breast cancer and their implications.
• To discuss key oncogenes and tumor suppressor genes involved in breast cancer.

Main Methods:

• Review of scientific literature on breast cancer biomarkers and genetic alterations.
• Analysis of common chromosomal gains and losses in breast cancer.
• Description of significant proto-oncogenes and tumor suppressor genes.

Main Results:

• Frequent genetic alterations in breast cancer include gains on chromosomes 1q, 8q, 17q, 20q, 11q and losses on 8p, 13q, 16q, 18q, 11q.
• These chromosomal regions harbor critical genes like BRCA1, BRCA2, p53, HER2-neu, cyclin D1, and cyclin E.
• Identification of these genetic changes aids in tumor prediction and individualized treatment.

Conclusions:

• Molecular biomarkers and genetic profiling are integral to modern breast cancer management.
• Understanding chromosomal alterations provides insights into breast cancer pathogenesis.
• Targeted therapies based on genetic biomarkers enhance treatment efficacy.